On 12 Nov 2026 Vertex Pharmaceuticals closed at $542.62, +19.7% this year; market cap $138.48bn, P/E 34.8.
Health Care · Biotechnology · NASDAQ · United States
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Market cap | $138.48bn |
| P/E (trailing) | 34.8 |
| EPS (TTM) | $15.58 |
| Beta | 0.28 |
| Dividend | $0.00 |
| Dividend yield | 0.00% |
| Ex-dividend date | — |
| Latest report | 2 Nov 2026 |
| Next earnings | 1 Feb 2027 |
| YTD | +19.7% |
| 1Y | +25.0% |
| 3Y | +12.7% |
| 5Y | +23.7% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $12.07bn | $3.95bn | $3.19bn |
| 2024 | $11.02bn | $-535.60m | $-790.30m |
| 2023 | $9.87bn | $3.62bn | $3.28bn |
| 2022 | $8.93bn | $3.32bn | $3.93bn |
| 2021 | $7.57bn | $2.34bn | $2.41bn |
We publish no single base value for Vertex Pharmaceuticals. Our valuation methods put it between $435.58 and $483.03 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.